Spyre Therapeutics (SYRE) Cash from Operations (2015 - 2026)

Spyre Therapeutics has reported Cash from Operations for 12 years, with the latest figure at 57372000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 39.95% year-over-year to 57372000.0; the trailing twelve-month figure through Mar 2026 stood at 185630000.0 (down 9.28% YoY), and the FY2025 full-year result was 169252000.0, down 7.52% from the prior year.
• Cash from Operations for Q1 2026 stood at 57372000.0, down from 44578000.0 in the prior quarter.
• The five-year high for Cash from Operations was 15068000.0 in Q3 2022, with the low at 62248000.0 in Q2 2024.
• Historically, Cash from Operations has averaged 33181647.06 across 5 years, with a median of 31036000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 1092.94% — and 2023, when it soared 32.86%.
• Spyre Therapeutics' Cash from Operations stood at 18140000.0 in 2022, then slumped by 71.09% to 31036000.0 in 2023, then decreased by 19.86% to 37199000.0 in 2024, then retreated by 19.84% to 44578000.0 in 2025, then declined by 28.7% to 57372000.0 in 2026.
• The last three Cash from Operations figures came in at 57372000.0 (Q1 2026), 44578000.0 (Q4 2025), and 37117000.0 (Q3 2025), per Business Quant data.